甲氨蝶呤暂停对类风湿关节炎患者季节性流感疫苗效力影响的随机临床试验
该前瞻性随机平行组试验将稳定剂量甲氨蝶呤治疗的类风湿关节炎患者按1:1:1:1分为四组,分别持续用药、接种前停药4周、接种前后各停药2周、接种后停药4周,评估流感疫苗应答。结果显示接种前后各停药2周组对三种抗原的满意疫苗应答率高于持续用药组,且抗H3N2和B-Yamagata抗体倍数增长更高,各组RA flare发生率无显著差异。
要点
- 接种前后各停甲氨蝶呤2周可提高RA患者流感疫苗满意应答率。
- 接种后停药4周亦改善抗H3N2和B-Yamagata抗体应答。
- 各组RA flare发生率无显著差异。
核心结论
- 暂时停用甲氨蝶呤可改善RA患者季节性流感疫苗的免疫原性。
研究设计与样本
- 前瞻性随机平行组试验,稳定剂量MTX的RA患者按1:1:1:1随机分为四组。
- 符合方案人群199例,四组分别为54、44、49和52例。
主要发现
- 第3组对三种抗原的满意疫苗应答率均高于第1组(51.0% vs 31.5%,p=0.044)。
- 抗H3N2抗体倍数增长第3组为12.2(95%CI 8.4-17.5,p<0.001),第4组为10.0(95%CI 6.8-14.8,p=0.043),均高于第1组5.9(95%CI 4.3-8.1)。
- 抗B-Yamagata抗体应答第3组为4.7(95%CI 3.3-6.7,p=0.048),第4组为6.1(95%CI 4.2-8.8,p<0.001),均高于第1组2.9(95%CI 2.2-3.8)。
- RA flare发生率四组分别为24.1%、21.2%、34.1%和38.8%(p=NS)。
关键数值与推荐
- 主要结局为接种后4周抗体滴度≥4倍增长的满意疫苗应答频率。
- 所有参与者接种含H1N1、H3N2和B-Yamagata的三价流感疫苗。
临床怎么用
- RA患者接种季节性流感疫苗时,可考虑在接种前后各暂停甲氨蝶呤2周以提高疫苗应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether temporary discontinuation of methotrexate (MTX) improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: In this prospective randomised parallel-group trial, patients with RA taking stable dose of MTX were randomly assigned at a ratio of 1:1:1:1 to continue MTX (group 1), suspend MTX for 4 weeks before vaccination (group 2), suspend MTX for 2 weeks before and 2 weeks after vaccination (group 3) or suspend MTX for 4 weeks after vaccination (group 4). All participants were vaccinated with trivalent influenza vaccine containing H1N1, H3N2 and B-Yamagata. The primary outcome was frequency of satisfactory vaccine response (≥4-fold titre increase 4 weeks postvaccination). Secondary endpoints included fold change in antibody titres from baseline. RESULTS: The per-protocol population consisted of 199 patients (n=54, 44, 49 and 52 in groups 1, 2, 3 and 4, respectively). Group 3 achieved higher satisfactory vaccine response against all three antigens than group 1 (51.0% vs 31.5%, p=0.044). The anti-H3N2 antibody fold increase (95% CI) was significantly higher in groups 3 and 4 (12.2 (8.4 to 17.5), p <0.001 and 10.0 (6.8 to 14.8), p=0.043, respectively) than group 1 (5.9 (4.3 to 8.1)). The anti-B-Yamagata antibody responses of groups 3 and 4 were higher (4.7 (3.3 to 6.7), p=0.048; 6.1 (4.2 to 8.8), p <0.001, respectively) than group 1 (2.9 (2.2 to 3.8)). RA flare occurred in 24.1%, 21.2%, 34.1% and 38.8% in groups 1, 2, 3 and 4, respectively (p=NS). CONCLUSIONS: Temporary MTX discontinuation improves the immunogenicity of seasonal influenza vaccination in patients with RA. TRIAL REGISTRATION: Trial registration number is: www.clinicaltrials.gov, NCT02748785.
引用
- Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017. PMID: 28468794. doi:10.1136/annrheumdis-2017-211128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。